← Back to Screener
Intelligent Bio Solutions Inc. Common Stock (INBS)
Price$2.93
Favorite Metrics
Price vs S&P 500 (26W)-83.89%
Price vs S&P 500 (4W)-31.94%
Market Capitalization$5.32M
All Metrics
Book Value / Share (Quarterly)$8.96
P/TBV (Annual)1.44x
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)91.13%
Cash Flow / Share (Quarterly)$-7.87
Price vs S&P 500 (YTD)-76.23%
Gross Margin (TTM)46.21%
Net Profit Margin (TTM)-315.37%
EPS (TTM)$-15.13
10-Day Avg Trading Volume0.06M
EPS Excl Extra (TTM)$-15.13
Revenue Growth (5Y)74.49%
EPS (Annual)$-20.04
ROI (Annual)-330.97%
Gross Margin (Annual)40.85%
Net Profit Margin (5Y Avg)-754.73%
Cash / Share (Quarterly)$0.60
Revenue Growth QoQ (YoY)47.62%
ROA (Last FY)-128.11%
Revenue Growth TTM (YoY)18.14%
EBITD / Share (TTM)$-13.11
ROE (5Y Avg)-185.33%
Operating Margin (TTM)-315.25%
Cash Flow / Share (Annual)$-13.53
P/B Ratio0.48x
P/B Ratio (Quarterly)0.35x
Net Income / Employee (Annual)$-1
EV / Revenue (TTM)1.28x
Net Interest Coverage (TTM)-3.75x
ROA (TTM)-99.23%
EPS Incl Extra (Annual)$-20.04
Current Ratio (Annual)0.77x
Quick Ratio (Quarterly)2.26x
3-Month Avg Trading Volume1.68M
52-Week Price Return-77.83%
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$6.32
P/S Ratio (Annual)1.74x
Asset Turnover (Annual)0.37x
52-Week High$24.90
Operating Margin (5Y Avg)-773.91%
EPS Excl Extra (Annual)$-20.04
26-Week Price Return-75.14%
Quick Ratio (Annual)0.59x
13-Week Price Return-82.95%
Total Debt / Equity (Annual)0.07x
Current Ratio (Quarterly)2.37x
Enterprise Value$4.596
Revenue / Share Growth (5Y)1.72%
Asset Turnover (TTM)0.31x
Revenue / Employee (Annual)$0
Pretax Margin (Annual)-347.41%
Cash / Share (Annual)$1.39
3-Month Return Std Dev96.72%
Net Income / Employee (TTM)$-1
ROE (Last FY)-352.74%
Net Interest Coverage (Annual)-110.59x
EPS Basic Excl Extra (Annual)$-20.04
Receivables Turnover (TTM)9.91x
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$-15.13
Receivables Turnover (Annual)0.76x
ROI (TTM)-192.00%
P/S Ratio (TTM)1.49x
Pretax Margin (5Y Avg)-757.22%
Revenue / Share (Annual)$5.79
Tangible BV / Share (Annual)$11.45
Forward P/E0.84x
Price vs S&P 500 (52W)-112.93%
Year-to-Date Return-72.09%
5-Day Price Return8.13%
EPS Normalized (Annual)$-20.04
ROA (5Y Avg)-80.78%
Net Profit Margin (Annual)-346.23%
Month-to-Date Return-20.48%
Cash Flow / Share (TTM)$-7.57
EBITD / Share (Annual)$-17.89
Operating Margin (Annual)-348.71%
LT Debt / Equity (Annual)0.00x
ROI (5Y Avg)-170.27%
LT Debt / Equity (Quarterly)0.00x
EPS Basic Excl Extra (TTM)$-15.13
P/TBV (Quarterly)0.50x
P/B Ratio (Annual)4.20x
Inventory Turnover (TTM)2.98x
Pretax Margin (TTM)-316.50%
Book Value / Share (Annual)$4.09
Price vs S&P 500 (13W)-85.81%
Beta4.42x
Revenue / Share (TTM)$3.77
ROE (TTM)-197.94%
52-Week Low$2.42
Analyst Recommendations
Dec 2024
Jan 2025
Feb 2025
Mar 2025
4.29
4.29
4.29
4.29
Industry Peers — Surgical & Medical Instruments(108)
| Symbol | P/S Ratio (TTM) | Revenue Growth (5Y) | Gross Margin (TTM) | Operating Margin (TTM) | Price |
|---|---|---|---|---|---|
INBSIntelligent Bio Solutions Inc. Common Stock | 1.49x | 74.49% | 46.21% | -315.25% | $2.93 |
SYKStryker Corporation | 5.17x | 11.84% | 64.57% | 19.43% | $338.34 |
BSXBoston Scientific Corp. | 4.58x | 15.16% | 69.01% | 18.00% | $60.99 |
MMM3M Company | 3.21x | -4.97% | 39.92% | 18.55% | $151.40 |
MDLNMedline Inc. Class A common stock | 2.20x | — | 26.44% | 7.78% | $48.26 |
BDXBecton, Dickinson and Co. | 2.06x | 6.32% | 46.42% | 12.15% | $158.64 |
RMDResMed Inc. | 6.07x | 11.72% | 60.85% | 33.70% | $226.14 |
DXCMDexCom, Inc. | 5.33x | 19.33% | 62.09% | 19.56% | $64.62 |
WSTWest Pharmaceutical Services, Inc. | 6.29x | 7.44% | 35.91% | 19.03% | $278.00 |
PODDInsulet Corporation | 5.19x | 24.53% | 71.63% | 12.92% | $200.87 |
PENPenumbra, Inc. | 9.24x | 20.16% | 67.14% | 13.48% | $329.71 |
About
Intelligent Bio Solutions Inc. is a life sciences company developing non-invasive diagnostic tests, including a biosensor platform for chronic disease monitoring and a portable drug screening solution that analyzes fingerprint sweat. The company's products offer real-time, hygienic alternatives to traditional diagnostic and substance screening methods. It operates across four geographic segments—United Kingdom, Asia Pacific, Americas, and Rest of World—with the United Kingdom representing its largest revenue source.